Seres Therapeutics, Inc. SEC filings MCRB
Seres Therapeutics, Inc. has 724 filings in SEC EDGAR's recent list, going back to Jun 9, 2014. Its latest annual report, Form 10-K, was filed on Mar 12, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-3 | Shelf registration | Aug 13, 2026 | — |
| 424B5 | Prospectus supplement | Aug 4, 2026 | — |
| S-8 | Employee stock plan registration | Jul 9, 2026 | — |
| S-8 | Employee stock plan registration | May 7, 2025 | — |
| S-8 | Employee stock plan registration | Mar 13, 2025 | — |
| 424B3 | Prospectus | Oct 11, 2024 | — |
| S-3 | Shelf registration | Oct 1, 2024 | — |
| S-8 | Employee stock plan registration | Mar 5, 2024 | — |
| S-3 | Shelf registration | Aug 8, 2023 | — |
| S-8 | Employee stock plan registration | Mar 7, 2023 | — |
| S-8 | Employee stock plan registration | Dec 30, 2022 | — |
| 424B5 | Prospectus supplement | Jun 30, 2022 | — |
| POS AM | Filing | May 4, 2022 | — |
| POS AM | Filing | Mar 1, 2022 | — |
| S-8 | Employee stock plan registration | Mar 1, 2022 | — |
| 424B5 | Prospectus supplement | May 21, 2021 | — |
| S-8 POS | Filing | Mar 3, 2021 | — |
| S-8 | Employee stock plan registration | Mar 2, 2021 | — |
| FWP | Free writing prospectus | Aug 17, 2020 | — |
| 424B5 | Prospectus supplement | Aug 14, 2020 | — |
| 424B5 | Prospectus supplement | Aug 14, 2020 | — |
| FWP | Free writing prospectus | Aug 13, 2020 | — |
| FWP | Free writing prospectus | Aug 13, 2020 | — |
| 424B5 | Prospectus supplement | Aug 11, 2020 | — |
| S-3ASR | Automatic shelf registration | Aug 11, 2020 | — |
| 424B5 | Prospectus supplement | Mar 18, 2020 | — |
| S-3 | Shelf registration | Mar 9, 2020 | — |
| S-8 | Employee stock plan registration | Mar 2, 2020 | — |
| 424B5 | Prospectus supplement | Nov 27, 2019 | — |
| 424B5 | Prospectus supplement | Jun 14, 2019 | — |
| 424B5 | Prospectus supplement | Jun 12, 2019 | — |
| S-8 | Employee stock plan registration | Mar 6, 2019 | — |
| S-8 | Employee stock plan registration | Mar 8, 2018 | — |
| S-3 | Shelf registration | Mar 16, 2017 | — |
| S-8 | Employee stock plan registration | Mar 14, 2016 | — |
| S-8 | Employee stock plan registration | Jun 26, 2015 | — |
| 424B4 | Prospectus | Jun 26, 2015 | — |
| S-1MEF | Form s-1mef | Jun 25, 2015 | — |
| S-1/A | Amended registration statement | Jun 24, 2015 | — |
| S-1/A | Amended registration statement | Jun 16, 2015 | — |
| S-1 | Registration statement | May 27, 2015 | — |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MCRB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1609809
- Former names
- Seres Therapeutics, Inc. (until Nov 4, 2026); Seres Health, Inc. (until May 14, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.